TargetRx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

targetrx.com

Founded Year

1999

Stage

Acquired | Acquired

Total Raised

$47.25M

About TargetRx

TargetRx, Inc., founded in December 1999 and headquartered in Horsham, Pennsylvania, is a provider of marketing information services to large pharmaceutical companies. The company uses internet-based physician surveys to build a database that is the basis for products that improve sales force productivity and marketing material effectiveness. TargetRx currently has two main products that generate the majority of their revenues; Detail Performance Monitor and Pro Sigma. The Detail Performance Monitor is focused on improving sales and marketing execution by providing pharmaceutical companies with clear information as to which sales messages and sales tactics are effective at increasing market share of their particular drugs. Pro Sigma is aimed at improving the development of promotional materials. This includes offerings to determine bundle of messages to use promoting a brand or sales pitch to use with physicians to increase usage of a brand. These offerings provide clients with confidence and precision as to whether their promotional campaign will be effective or not and how they can improve it prior to going to market.

TargetRx Headquarter Location

220 Gibraltar Road Suite 200

Horsham, Pennsylvania, 19044,

United States

215-444-8700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

TargetRx Patents

TargetRx has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/26/2006

6/7/2011

Market segmentation, Market research, Marketing strategy, Marketing, Promotion and marketing communications

Grant

Application Date

5/26/2006

Grant Date

6/7/2011

Title

Related Topics

Market segmentation, Market research, Marketing strategy, Marketing, Promotion and marketing communications

Status

Grant

Latest TargetRx News

China Digest: GP Capital leads $26m Series B in Baijiayun; TargetRx raises $14m

Sep 18, 2020

Photo: Baijiayun September 18, 2020 Baijiayun has secured 178 million yuan ($26 million) in a Series B round of financing led by existing investor GP Capital, while Shenzhen Targetrx has garnered nearly 100 million yuan ($14 million) from Hongtai Aplus. Baijiayun nets $26m in a Series B round  Baijiayun, a provider of one-stop video technology services, announced on Friday that it has raised 178 million yuan ($26 million) in a Series B round of financing led by existing investor GP Capital, an investment arm of state-owned Shanghai International Group. The investors who participated in the round include Chinese Academy of Science’s investment vehicle CASH Capital, Qinglan Capital, Shenzhen Houde Qianhai Investment, and Baijiayun’s employees, the company posted on WeChat. Education-focused Taoli Capital and Hailan Capital served as financial advisors. The fresh proceeds will be used to expand Baijiayun’s sales network, facilitate product R&D, and strengthen talent. Baijiayun, which started operations in 2017 in Beijing, primarily develops cloud-based video software-as-a-service (SaaS) for the education and training industry. Its one-stop service comprises live streaming, video conferencing, online courses, and virtual training. Besides, it also caters to a slew of areas such as finance and healthcare. “With the fresh round of funding, we expect Baijiayun to continue to help more enterprises through innovative products and services,” said Haoxiang Hou, partner, GP Capital, in the statement. GP Capital, along with state-backed CITIC Capital, Gaorong Capital, QF Capital, and others had collectively invested in Baijiayun in an angel round in 2017. Additionally, it was also backed by Baidu, Bondshine Capital, and Guiyang Venture Capital, among others. Shenzhen Capital-backed TargetRx bags nearly $14m Oncology drug maker Shenzhen Targetrx, Inc, also known as TargetRx, has closed a nearly 100 million yuan ($14 million) strategic investment from Hongtai Aplus, a 30 billion yuan ($4.4 billion) investment fund with a focus on AI, big data, smart manufacturing, consumption and education, and healthcare. The fundraising follows an undisclosed investment from CCB International’s Beijing Jianxing Medical Fund and Shenzhen Zhonghe Ruimin Investment in July. TargetRx will allocate the proceeds to accelerate the development of new drugs, it said in a statement on Friday. Founded by Dr. Yihan Wang in 2014, TargetRx is a small-molecule-based biopharma firm that develops effective and safe anti-cancer drugs. The flagship drug candidate, TGRX-678, in June this year received clinical trial approval from the Center for Drug Evaluation, NMPA. The firm has got over 180 patents in China and beyond. State-owned Shenzhen Capital Group had together with CCB International, Oriental Fortune Capital, and Tsing-Yuan Capital infused 150 million yuan ($22 million) in TargetRx’s Series A round in April 2020. In 2018, Shenzhen Capital had also joined hands with other investors collectively pouring “millions of US dollars” in its Pre-A round.

  • When was TargetRx founded?

    TargetRx was founded in 1999.

  • Where is TargetRx's headquarters?

    TargetRx's headquarters is located at 220 Gibraltar Road, Horsham.

  • What is TargetRx's latest funding round?

    TargetRx's latest funding round is Acquired.

  • How much did TargetRx raise?

    TargetRx raised a total of $47.25M.

  • Who are the investors of TargetRx?

    Investors of TargetRx include ImpactRx, New Enterprise Associates, Domain Associates, Quaker BioVentures, Cross Creek and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.